Publications
Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, Small EJ, Link TM. CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. Journal of vascular and interventional radiology : JVIR. 2017. PMID: 28549709
Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, Small EJ, Link TM. CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. Journal of vascular and interventional radiology : JVIR. 2017. PMID: 28549709
Nikkilä J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, Monni V, Harris RS, Pettitt SJ, Ashworth A, Lord CJ. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. British journal of cancer. 2017. PMID: 28535155
Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Annals of hematology. 2017. PMID: 28534184
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017. PMID: 28533223
Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, Morris MJ, Small E, Hahn O, Humphrey P, Taylor J, Marshall J. Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU international. 2017. PMID: 28437029
Michelle E. Melisko, Edward Kenji Hadeler, Sandahl H Nelson, Audrey Lunde, Irene Acerbi, Hope S. Rugo, Melanie Catherine Majure, Amy Jo Chien, Laura Esserman, Sheri J. Hartman. Objective assessment of physical activity during chemotherapy for breast cancer. Journal of Clinical Oncology. 2017. PMID:
Daniel Kwon, Claire Mulvey, Alan T Paciorek, Hilary Chan, Lingzhong Meng, Li Zhang, Eric K. Nakakura, Nicholas Fidelman, Emily K. Bergsland, Katherine Van Loon. Periprocedural management of patients undergoing liver resection or liver-directed therapy for neuroendocrine tumor metastases. Journal of Clinical Oncology. 2017. PMID:
Jessica K. Altman, Alexander E. Perl, Jorge E. Cortes, Catherine Choy Smith, Mark Robert Litzow, Jason E Hill, Richard A. Larson, Charles Liu, Ellen K. Ritchie, Stephen Anthony Strickland, Eunice S. Wang, Andreas Neubauer, Giovanni Martinelli, Erkut Bahceci, Mark J. Levis. Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology. 2017. PMID:
Victoria Wang, Gabriel N. Mannis, Rebecca Leah Olin, Aaron Logan, Thomas G. Martin, Lloyd Earl Damon, Danielle Kilayko, Pamela N. Munster, Charalambos Andreadis. CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML). Journal of Clinical Oncology. 2017. PMID:
Daud A, Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. The oncologist. 2017. PMID: 28526719
Ozawa H, Ranaweera RS, Izumchenko E, Makarev E, Zhavoronkov A, Fertig EJ, Howard JD, Markovic A, Bedi A, Ravi R, Perez J, Le QT, Kong CS, Jordan RC, Wang H, Kang H, Quon H, Sidransky D, Chung CH. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017. PMID: 28522603
Daud A, Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. The oncologist. 2017. PMID: 28526719
Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017. PMID: 28522741
Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017. PMID: 28522741
Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, Hofree M, Romanel A, Osborne JR, Kim JW, Azabdaftari G, Woloszynska-Read A, Sfanos K, De Marzo AM, Demichelis F, Gabriel S, Van Allen EM, Mesirov J, Tamayo P, Rubin MA, Powell IJ, Garraway LA. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer discovery. 2017. PMID: 28515055
Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. The oncologist. 2017. PMID: 28507205
Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. The oncologist. 2017. PMID: 28507205
Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast cancer research and treatment. 2017. PMID: 28503722
Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast cancer research and treatment. 2017. PMID: 28503722